Aeterna Zentaris (TSE:AEZS) Shares Down 6.4%

Aeterna Zentaris Inc. (TSE:AEZS) shares were down 6.4% during trading on Monday . The stock traded as low as C$8.20 and last traded at C$8.20. Approximately 1,475 shares traded hands during trading, an increase of 78% from the average daily volume of 828 shares. The stock had previously closed at C$8.76.

Aeterna Zentaris Stock Performance

The firm has a 50-day moving average price of C$8.02 and a 200 day moving average price of C$4.54. The firm has a market capitalization of C$9.92 million, a PE ratio of -0.44 and a beta of 2.08. The company has a quick ratio of 9.37, a current ratio of 8.01 and a debt-to-equity ratio of 1.53.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.